BCTXL
BriaCell Therapeutics Corp.
Price Chart
Latest Quote
$0.90
| Previous Close | $0.95 |
| Open | $1.08 |
| Day High | $0.95 |
| Day Low | $0.90 |
| Volume | 2,619 |
Stock Information
| Cash Equivalents | $22.80M |
| Net Income | $-30.68M |
| Exchange | NCM |
📊 Comprehensive Analysis
Company Data
| Income | $-30.68M |
| Book/sh | $3.32 |
Financial Ratios
| Quick Ratio | 6.35 |
| Current Ratio | 7.07 |
Returns & Margins
| ROA | -90.84% |
| ROE | -175.25% |
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
| P/B | 0.28 |
Analyst Data
| Recommendation | none |
Technical Indicators
| Shares Float | 7.86M |
| Volatility | 1.54 |
Performance History
| YTD | +0.00% |
Sign up for free to view detailed scoring breakdown — premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $0.92 | 10,052 |
About BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.
📰 Latest News
Is CRA International’s New Bria-IMT Role Quietly Redefining Its Healthcare Moat and Pricing Power (CRAI)?
Simply Wall St. • 2026-07-18T03:15:11Z